Revance Therapeutics, Inc.

RVNC

US7613301099

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 13:00:00 2024-07-03 EDT			5-day change	1st Jan Change
2.68 ^USD	+10.74%		+3.88%	-69.51%

07-01	Revance Therapeutics, Inc.(NasdaqGM:RVNC) added to Russell 3000E Index	CI
07-01	Revance Therapeutics, Inc.(NasdaqGM:RVNC) added to Russell Microcap Index	CI

Revance Therapeutics, Inc. Provides Earnings Guidance for the Year 2020

January 14, 2021 at 03:40 pm

Revance Therapeutics, Inc. provided earnings guidance for the year 2020. The company expects full-year 2020 revenue to come in at $12.5 million to $13 million range in fourth quarter.

Latest news about Revance Therapeutics, Inc.

Revance Therapeutics, Inc.(NasdaqGM:RVNC) added to Russell 3000E Index	06-30	CI
Revance Therapeutics, Inc.(NasdaqGM:RVNC) added to Russell Microcap Index	06-30	CI
Revance Therapeutics, Inc.(NasdaqGM:RVNC) added to Russell Microcap Growth Index	06-30	CI
Revance Therapeutics, Inc.(NasdaqGM:RVNC) added to Russell 3000E Growth Index	06-30	CI
Revance Therapeutics, Inc.(NasdaqGM:RVNC) dropped from S&P Pharmaceuticals Select Industry Index	06-23	CI
Transcript : Revance Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:00 AM	06-11
Needham Adjusts Price Target on Revance Therapeutics to $12 From $18, Maintains Buy Rating	05-10	MT
Piper Sandler Cuts Price Target on Revance Therapeutics to $11 From $20, Maintains Overweight Rating	05-10	MT
Earnings Flash (RVNC) REVANCE THERAPEUTICS Reports Q1 Revenue $51.9M, vs. Street Est of $56.7M	05-09	MT
Revance Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Transcript : Revance Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
Revance Therapeutics, Inc. Announces the Commercial Launch of DAXXIFY (Daxibotulinumtoxina-Lanm) for Injection for the Treatment of Cervical Dystonia	05-09	CI
Certain Restricted Stock Units of Revance Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-MAY-2024.	05-03	CI
Certain Common Stock of Revance Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-MAY-2024.	05-03	CI
AbbVie raises annual profit forecast on strong Skyrizi sales	04-26	RE
Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	04-12	CI
Transcript : Revance Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 09:30 AM	03-12
North American Morning Briefing: Stock Futures Fall With Investor Focus on Inflation Data	03-11	DJ
Revance Therapeutics Prices $100 Million Public Offering	03-04	MT
Goldman Sachs Adjusts Price Target on Revance Therapeutics to $9 From $8, Maintains Neutral Rating	03-01	MT
Needham Cuts Price Target on Revance Therapeutics to $18 From $20, Maintains Buy Rating	02-29	MT
Piper Sandler Cuts Price Target on Revance Therapeutics to $20 From $42, Maintains Overweight Rating	02-29	MT
Transcript : Revance Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	02-28
Earnings Flash (RVNC) REVANCE THERAPEUTICS Posts Q4 Revenue $69.8M	02-28	MT
Revance Therapeutics, Inc. Provides Revenue Guidance for the Year 2024	02-28	CI

Chart Revance Therapeutics, Inc.

Duration

Period

More charts

Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The Company has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.

Sector

Pharmaceuticals

Calendar

2024-08-05 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Revance Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.68 USD

Average target price

13.5 USD

Spread / Average Target

+403.73%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
REVANCE THERAPEUTICS, INC.	-69.51%	280M
CSL LIMITED	+4.61%	96.72B
SAMSUNG BIOLOGICS CO.,LTD.	+5.66%	41.43B
BIOGEN INC.	-13.20%	32.7B
UCB	+79.53%	29.06B
BIOMARIN PHARMACEUTICAL INC.	-16.02%	15.38B
INCYTE CORPORATION	-8.17%	12.97B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-13.35%	11.36B
ALTEOGEN INC.	+160.91%	9.9B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-56.29%	8.79B

Biopharmaceuticals